Nucleic acid aptamers

1. A nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer, wherein the aptamer is aptamer-1 (SEQ ID NO:2323) or aptamer-41 (SEQ ID NO:2363).

2. The nucleic acid molecule of claim 1 , wherein the aptamer is aptamer-1 (SEQ ID NO:2323).

3. The nucleic acid molecule of claim 1 , wherein the aptamer is aptamer-41 (SEQ ID NO:2363).

4. The nucleic acid molecule of claim 1 , wherein the nucleotides are RNA.

5. The nucleic acid molecule of claim 4 , wherein the RNA includes a modified nucleotide.

6. The nucleic acid molecule of claim 5 , wherein the RNA is chemically modified (2′-fluoropyridines).

7. A conjugate comprising the nucleic acid molecule of claim 1 linked to a therapeutic or diagnostic molecule.

8. The conjugate of claim 7 , wherein the therapeutic molecule is an RNAi molecule.

9. The conjugate of claim 8 , wherein the RNAi molecule is an siRNA molecule or an miRNA molecule.

10. The conjugate of claim 9 , wherein the siRNA specifically targets Nx1 NADPH oxidase.

11. A method for delivering a therapeutic or diagnostic molecule to a vascular smooth muscle cell, comprising contacting the cell with the conjugate of claim 7 .

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and

(i) a nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer, wherein the aptamer is aptamer-1 (SEQ ID NO:2323) or aptamer-41 (SEQ ID NO:2363); or

(ii) conjugate comprising the a nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer, wherein the aptamer is aptamer-1 (SEQ ID NO:2323) or aptamer-41 (SEQ ID NO:2363) operably linked to a therapeutic or diagnostic molecule.

13. An article of manufacture comprising a solid substrate coated with the molecule of claim 1 .

14. The article of claim 13 , wherein the solid substrate is a stent, catheter, a catheter hub, a catheter port, or a non-degradable implant.